Edwards Lifesciences is executing a successful growth pivot, with revenue accelerating from 6.2% in 2025Q1 to 16.7% in 2026Q1, driven by TAVR volume and early TMTT adoption. Gross margins have remained resilient near 78% despite product mix dilution, while ope...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 16.7% in 2026Q1 with gross margin stable at 78.2%, while operating margin expanded to 29.8% in 2026Q2 from 22.6% in 2024Q4, though net income volatility persists due to one-time items.
Edwards Lifesciences benefits from strong institutional support, which bolsters investor confidence and stability.
Expected product approvals present significant growth potential, driving future revenue and market expansion.
The company's leadership in structural heart therapies positions it for sustained growth in the medtech sector.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 23, 2026 | $0.78+5.0% vs $0.74 | $1.7B+2.4% vs $1.7B |
Q2 2026 Apr 23, 2026 | $0.78+7.0% vs $0.73 | $1.6B+3.2% vs $1.6B |
Q1 2026 Feb 10, 2026 | $0.58-6.1% vs $0.62 | $1.6B+1.5% vs $1.5B |
Q4 2025 Oct 30, 2025 | $0.67+12.4% vs $0.60 | $1.6B+3.7% vs $1.5B |
Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
On September 16, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has experienced a mixed price performance recently. The
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.
Benchmark EW against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Edwards Lifesciences Corporation (EW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $88.78 | $51.12B | 48.51 | 11.55% | 17.69% | 10.52% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $103.73 | $180.68B | 27.88 | 5.67% | 13.91% | 12.09% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $275.07 | $105.45B | 32.75 | 11.16% | 14.43% | 16.36% | — | |
| $93.98 | $18.18B | 26.47 | 7.2% | 9.48% | 6.36% | — |
Edwards Lifesciences Corporation (EW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Edwards Lifesciences Corporation (EW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
May 8, 2026·SEC
May 4, 2026·SEC
Get notified when EW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Edwards Lifesciences Corporation (EW) stock FAQ — growth, dividends, profitability & financials explained
Edwards Lifesciences Corporation (EW) reported $6.51B in revenue for fiscal year 2025. This represents a 620% increase from $905.0M in 1999.
Edwards Lifesciences Corporation (EW) grew revenue by 11.5% over the past year. This is steady growth.
Yes, Edwards Lifesciences Corporation (EW) is profitable, generating $1.00B in net income for fiscal year 2025 (17.7% net margin).
Edwards Lifesciences Corporation (EW) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.
Edwards Lifesciences Corporation (EW) generated $1.43B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
